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論 文 内 容 の 要 旨 
Introduction 
Ovarian cancers are a major cause of mortality worldwide. Because almost of them have 
becomes resistant to chemotherapy after surgical debulking. More recently, it has been 
hypothesized that functional heterogeneity in the tumor may account for the fact that not all 
of the cancer cells in solid tumors have a similar ability to drive tumor formation (Reya T et 
al., 2001). It has led to the cancer stem cell (CSC) hypothesis. CSCs are defined as a 
minority cell type in the tumor, which retains the capacity, through asymmetric division, for 
self-renewal as well as differentiation into multiple cell types. Through this process, CSCs 
can regenerate the entire tumor phenotype and subsequent metastases. Relatively successful 
cancer treatments shrink the bulk of tumor cells, but of the fail to eliminate the CSCs 
(Cabanilas R et al., 2009). 
 Attention has been paid to CSCs as a new target cell for treating cancer. However, no 
method of identifying specific CSCs has been established in primary human ovarian 
carcinoma. The aim of this research was to identify a new combination of surface markers 
for human ovarian CSCs. 
 
Materials and Methods 
The tumor tissues were obtained from different ovarian cancer patiens during surgical 
procedures. The study was approved with policites of the Research Ethics Committee of the 
University of Toyama and consent was obtained from the patient. After the cells isolated, 
they have been keeping in the culture and transplanted serially into subcautaneous of mice. 
The isolated cells were classified according to the cell surface marker, CD24 and/or SSEA4 
with MACS (separator Magnetic cell sorting). They were stained with 
immunocytochemistry and analyzed with PCR for stemness marker. Also it was examined 
for sphere formation, flow cytometric (FCM) analysis, colony assay, chemotherapy 
resistance assay and tumorigenicity with xenotransplantation. 
 
Results 
By using RT-PCR methods, we found that the cultured cells strongly expressed stemness 
genes, such as c-myc, oct3/4, sox2, nanog, abcg-2 and bmi-1. They also expressed surface 
markers such as CD24, SSEA4, CD133 and CD47. However, there are no big difference 
about the rate of gene expression between CD133+ and CD133-. The sub-population of 
CD24+ SSEA4+ cells expressed Oct-4 strongly, and was able to form spheres much more 
than CD24 single positive cells or CD24 and SSEA4 double negative cells. Only five 
CD24+SSEA4+ cells made spheres within three weeks. This sub-population formed the 
most numbers of colonies in the soft agar colonies assay. The CD24+SSEA4+ cells grew 
better in the presence of cisplatin better than other sub-populations. With injection of only 
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100 cells per mouse, CD24+SSEA4+ cells were tumorigenic in all scid mice (4/4), with two 
months. 
 
Discussion 
 We described the isolation and characterization of a highly tumorigenic subpopulation of 
cells, cancer stem cells (CSCs), from human ovarian adenocarcinomas. Five separate 
criteria have been established for CSCs: a) self-renewal, b) small minority of the total tumor 
population, c) reproducible tumor phenotype, d) multipotent differentiation into 
nontumorigenic cells, and e) distinct cell surface antigenic phenotype, permitting consistent 
isolation (Dalerba P et al., 2007. Clarke MF et al., 2006).  
 In the present study, we selected subpopulation from primary ovarian cancer as CD24 and 
SSEA4 for the marker of CSCs. CD24 has been used as a cell surface marker of CSCs in 
hepatocarcinoma, prostate, clearcell renal carcinoma and ovarian cancer. SSEA4 is known 
as the stemness marker on the ES or iPS cells, but there are no reports about CSCs. The 
expression of SSEA-4 was found to increase from normal epithelium to benign 
cystademona and to borderline cystadenoma and adnocarcinoma in both serous mucinous 
groups. Loss or reduction of the expression of SSEA-4 was significantly correlated with 
more advanced tumor stage and poorer tumor cell differentiation.  This result was the 
opposite of our data. Nato et al. (2013) reported that CD44 and SSEA4 positive cells in an 
oral cancer cell live HSC-4 possess cancer stem cell characteristics. And SSEA4 was 
considered to be a new marker for cancer stem cell. CD133 is considered to be a cell 
surface marker of CSCs in melanoma, ovarian cancer and so on, too. However, our data was 
not difference the rate of stemness related gene expression between CD133+ and CD133-. 
 CD24+SSEA4+ cells were tumorigenic in all scid mice (4/4), with 2 month. In 
contrast no tumor was observed when 5.0x105 cells of CD24- cells. They were 
5,000 times more tumorigenic than CD24- cells. In accord with the hypothesis 
that CSCs are resistant to chemotherapy and radiotherapy these standard 
therapies fail to completely eradicate CSCs resulting in recurrence. We showed 
that the CD24+SSEA4+ cells were more resistant to cisplatin than other types.  
These results suggested that these CD24+SSEA4+ cells in ovarian cancer could 
survive under the exposure to the existing anti-cancer therapies and cause 
recurrence. 
 
Conclution 
 Based on these findings, it is suggested that CD24 and SSEA4 double positive 
cells have the characteristics of human ovarian tumor CSCs. It should be 
possible to develop an effective new clinical therapy using these cells as a target 
cell for human ovarian cancer.  
